{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:54:50Z","timestamp":1789181690980,"version":"build-2803163510"},"reference-count":32,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"\n Importance<\/jats:title>\n Substantial improvements in childhood cancer survival have created a critical need to address serious long-term health complications, such as valvular heart disease (VHD).<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To identify treatment-related risk factors for VHD in a large European cohort of long-term childhood cancer survivors.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This nested case-control study used data from the PanCareSurFup (PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies) and ProCardio cohorts, including detailed radiation dose reconstruction and chemotherapy exposure, for childhood cancer survivors from 7 European countries, diagnosed between 1940 and 2009, who survived at least 5 years after cancer diagnosis. Case patients, defined as having symptomatic VHD, were matched with controls 1:2 by subcohort, sex, age at cancer diagnosis, and calendar year of initial diagnosis. Data were analyzed from October 2023 to June 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Doses were calculated by performing a whole-body dosimetric reconstruction using a voxel-based anthropomorphic phantom with more than 200 delineated anatomic structures or substructures. Cumulative dose to cytotoxic agents was also assessed.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measure<\/jats:title>\n Development of symptomatic VHD (grade \u22653 per the Common Terminology and Criteria for Adverse Events, version 4.03).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of the 225 cases, 136 participants (60.4%) were male, and 195 (86.7%) were diagnosed with VHD beyond 20 years from childhood cancer. Survivors receiving a mean heart radiation therapy (RT) dose of 5 to less than 15 Gy had an increased risk of VHD (odds ratio [OR], 4.7; 95% CI, 2.1-10.7) compared to those without heart RT, with higher risk when more than half of the heart was exposed. The heart RT dose response appeared exponential, with the OR being 104.1 (95% CI, 27.8-389.6) for mean heart dose of 30 Gy or more, increasing considerably with follow-up from 6.0 (95% CI, 1.4-26.5) after 5 to 19 years to 71.4 (95% CI, 20.4-250.0) after 30 or more years. Cumulative anthracycline doses of 400 mg\/m\n 2<\/jats:sup>\n or higher were also associated with increased VHD risk (OR, 3.8; 95% CI, 1.4-10.3), showing an exponential dose-response pattern. Cumulative exposure to platinum agents was associated with VHD risk in a linear manner. No statistically significant associations were found for other chemotherapy agents or radiation to the spleen.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion and Relevance<\/jats:title>\n In this case-control study, heart RT, anthracyclines, and platinum agents were associated with increased VHD risk in childhood cancer survivors. Risks from both RT and anthracyclines were amplified with age and follow-up, underscoring the need for long-term cardiac surveillance.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2025.3863","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T15:00:47Z","timestamp":1760022047000},"page":"1449","source":"Crossref","is-referenced-by-count":7,"title":["Risk Factors for Valvulopathy Among Childhood Cancer Survivors"],"prefix":"10.1001","volume":"11","author":[{"given":"Rivalin","family":"Aho Glele","sequence":"first","affiliation":[{"name":"Radiation Epidemiology Group, INSERM, Unit 1018-CESP, Villejuif, France"},{"name":"Gustave Roussy, Villejuif, France"},{"name":"University of Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A. M.","family":"Feijen","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brice","family":"Fresneau","sequence":"additional","affiliation":[{"name":"Radiation Epidemiology Group, INSERM, Unit 1018-CESP, Villejuif, France"},{"name":"Gustave Roussy, Villejuif, France"},{"name":"University of Paris-Saclay, Villejuif, France"},{"name":"Department of Children and Adolescents Oncology, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoul C.","family":"Reulen","sequence":"additional","affiliation":[{"name":"Centre for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, England, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigue S.","family":"Allodji","sequence":"additional","affiliation":[{"name":"Radiation Epidemiology Group, INSERM, Unit 1018-CESP, Villejuif, France"},{"name":"Gustave Roussy, Villejuif, France"},{"name":"University of Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giao","family":"Vu-Bezin","sequence":"additional","affiliation":[{"name":"Radiation Epidemiology Group, INSERM, Unit 1018-CESP, Villejuif, France"},{"name":"Gustave Roussy, Villejuif, France"},{"name":"University of Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Radiation Epidemiology Group, INSERM, Unit 1018-CESP, Villejuif, France"},{"name":"Gustave Roussy, Villejuif, France"},{"name":"University of Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neige","family":"Journy","sequence":"additional","affiliation":[{"name":"Radiation Epidemiology Group, INSERM, Unit 1018-CESP, Villejuif, France"},{"name":"Gustave Roussy, Villejuif, France"},{"name":"University of Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Minard-Colin","sequence":"additional","affiliation":[{"name":"Department of Children and Adolescents Oncology, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bagnasco","sequence":"additional","affiliation":[{"name":"Epidemiology and Biostatistics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edit","family":"Bardi","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine, Johannes Kepler University Linz, Kepler University Hospital, Linz, Austria"},{"name":"St. Anna Children\u2019s Cancer Research Institute (CCRI), St. Anna Children\u2019s Hospital, Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabi\u00ebn N.","family":"Belle","sequence":"additional","affiliation":[{"name":"Childhood Cancer Research Group, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianne","family":"Byrne","sequence":"additional","affiliation":[{"name":"Boyne Research Institute, Drogheda, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira C.","family":"van Dalen","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jop C.","family":"Teepen","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree","family":"Grabow","sequence":"additional","affiliation":[{"name":"Division of Childhood Cancer Epidemiology, German Childhood Cancer Registry (GCCR), Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kaatsch","sequence":"additional","affiliation":[{"name":"Division of Childhood Cancer Epidemiology, German Childhood Cancer Registry (GCCR), Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Hjorth","sequence":"additional","affiliation":[{"name":"Skane University Hospital, Department of Clinical Sciences, Lund, Paediatrics, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momcilo","family":"Jankovic","sequence":"additional","affiliation":[{"name":"Pediatric Hematology Unit, San Gerardo Hospital, Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia E.","family":"Kuehni","sequence":"additional","affiliation":[{"name":"Childhood Cancer Research Group, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland"},{"name":"Pediatric Hematology\/Oncology, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Levitt","sequence":"additional","affiliation":[{"name":"Department of Paediatric and Adolescent Haematology and Oncology, Children\u2019s BMT Unit, Great North Children\u2019s Hospital, Newcastle upon Tyne, England, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Veres","sequence":"additional","affiliation":[{"name":"Gustave Roussy, Villejuif, France"},{"name":"INSERM Unit 1030, Villejuif, France"},{"name":"Department of Radiation Oncology, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Aerts","sequence":"additional","affiliation":[{"name":"SIREDO Oncology Center (Care, Innovation and Research for Children and AYA with Cancer), RTOP (Recherche Translationelle en Oncologie Pediatrique), U830 INSERM, Institut Curie, PSL Research University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Zadravec Zaletel","sequence":"additional","affiliation":[{"name":"Institute of Oncology, Ljubljana, Slovenia"},{"name":"Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena J. H.","family":"van der Pal","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Ronckers","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, the Netherlands"},{"name":"Division of Childhood Cancer Epidemiology, German Childhood Cancer Registry (GCCR), Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Sacerdote","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and AOU Citta della Salute e della Scienza, CPO-Piemonte, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick","family":"Skinner","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, England, United Kingdom"},{"name":"Great North Children\u2019s Hospital, Royal Victoria Infirmary, Newcastle upon Tyne, England, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Jakab","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Markusovszky Hospital, Szombathely, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Michel","sequence":"additional","affiliation":[{"name":"Faculty of Health Science and Medicine, University of Lucerne, Lucerne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Terenziani","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Haddy","sequence":"additional","affiliation":[{"name":"Radiation Epidemiology Group, INSERM, Unit 1018-CESP, Villejuif, France"},{"name":"Gustave Roussy, Villejuif, France"},{"name":"University of Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Thierry-Chef","sequence":"additional","affiliation":[{"name":"Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain"},{"name":"Universitat Pompeu Fabra, Barcelona, Spain"},{"name":"Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Cardis","sequence":"additional","affiliation":[{"name":"Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain"},{"name":"Universitat Pompeu Fabra, Barcelona, Spain"},{"name":"Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahima","family":"Diallo","sequence":"additional","affiliation":[{"name":"Gustave Roussy, Villejuif, France"},{"name":"INSERM Unit 1030, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Winter","sequence":"additional","affiliation":[{"name":"Centre for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, England, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leontien C. M.","family":"Kremer","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike M.","family":"Hawkins","sequence":"additional","affiliation":[{"name":"Centre for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, England, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"de Vathaire","sequence":"additional","affiliation":[{"name":"Radiation Epidemiology Group, INSERM, Unit 1018-CESP, Villejuif, France"},{"name":"Gustave Roussy, Villejuif, France"},{"name":"University of Paris-Saclay, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"coi250061r1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1470-2045(13)70548-5","article-title":"Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5\u2013a population-based study.","volume":"15","author":"Gatta","year":"2014","journal-title":"Lancet Oncol"},{"issue":"15","key":"coi250061r2","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/NEJMsa060185","article-title":"Chronic health conditions in adult survivors of childhood cancer.","volume":"355","author":"Oeffinger","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"coi250061r3","first-page":"483","article-title":"Solid malignant neoplasms after childhood irradiation: decrease of the relative risk with time after irradiation.","volume":"318","author":"de Vathaire","year":"1995","journal-title":"C R Acad Sci III"},{"issue":"22","key":"coi250061r4","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1001\/jama.2011.747","article-title":"Long-term risks of subsequent primary neoplasms among survivors of childhood cancer.","volume":"305","author":"Reulen","year":"2011","journal-title":"JAMA"},{"issue":"8","key":"coi250061r5","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1200\/JCO.2008.20.2267","article-title":"Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer.","volume":"28","author":"Tukenova","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi250061r6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.7326\/M15-0424","article-title":"Cardiac outcomes in adult survivors of childhood cancer exposed to cardiotoxic therapy: a cross-sectional study.","volume":"164","author":"Mulrooney","year":"2016","journal-title":"Ann Intern Med"},{"issue":"1","key":"coi250061r7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ijrobp.2014.09.010","article-title":"Valvular abnormalities detected by echocardiography in 5-year survivors of childhood cancer: a long-term follow-up study.","volume":"91","author":"van der Pal","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"coi250061r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109479","article-title":"The risk of valvular heart disease in the French Childhood Cancer Survivors\u2019 Study: contribution of dose-volume histogram parameters.","volume":"180","author":"Chounta","year":"2023","journal-title":"Radiother Oncol"},{"issue":"4","key":"coi250061r9","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv008","article-title":"Risk of valvular heart disease after treatment for Hodgkin lymphoma.","volume":"107","author":"Cutter","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"coi250061r10","doi-asserted-by":"publisher","first-page":"b4606","DOI":"10.1136\/bmj.b4606","article-title":"Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort.","volume":"339","author":"Mulrooney","year":"2009","journal-title":"BMJ"},{"issue":"4","key":"coi250061r11","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S0735-1097(03)00759-9","article-title":"Asymptomatic cardiac disease following mediastinal irradiation.","volume":"42","author":"Heidenreich","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"coi250061r12","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma.","volume":"109","author":"Aleman","year":"2007","journal-title":"Blood"},{"issue":"3","key":"coi250061r13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10654-018-0370-3","article-title":"The PanCareSurFup cohort of 83,333 five-year survivors of childhood cancer: a cohort from 12 European countries.","volume":"33","author":"Grabow","year":"2018","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"coi250061r15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1200\/JCO.21.02944","article-title":"Risk factors for heart failure among pan-European childhood cancer survivors: a PanCareSurFup and ProCardio cohort and nested case-control study.","volume":"41","author":"de Baat","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"coi250061r17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162778","article-title":"Late cardiac events after childhood cancer: methodological aspects of the pan-European study PanCareSurFup.","volume":"11","author":"Feijen","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"coi250061r18","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1088\/0031-9155\/57\/2\/473","article-title":"Total heart volume as a function of clinical and anthropometric parameters in a population of external beam radiation therapy patients.","volume":"57","author":"Badouna","year":"2012","journal-title":"Phys Med Biol"},{"issue":"5","key":"coi250061r19","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.ijrobp.2014.08.335","article-title":"Retrospective reconstructions of active bone marrow dose-volume histograms.","volume":"90","author":"Veres","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"coi250061r20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.canrad.2007.03.001","article-title":"Quality assurance of a virtual simulation software: application to IMAgo and SIMAgo (ISOgray).","volume":"11","author":"Isambert","year":"2007","journal-title":"Cancer Radiother"},{"key":"coi250061r22","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.4103\/jcecho.jcecho_5_19","article-title":"Valvular damage.","volume":"30","author":"Monte","year":"2020","journal-title":"J Cardiovasc Echogr"},{"issue":"20","key":"coi250061r23","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.116.022514","article-title":"Cardiac mortality among 200?000 five-year survivors of cancer diagnosed at 15 to 39 years of age: the Teenage and Young Adult Cancer Survivor Study.","volume":"134","author":"Henson","year":"2016","journal-title":"Circulation"},{"issue":"13","key":"coi250061r24","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1200\/JCO.18.01764","article-title":"Therapy-related cardiac risk in childhood cancer survivors: an analysis of the Childhood Cancer Survivor Study.","volume":"37","author":"Bates","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi250061r25","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/pbc.22664","article-title":"Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies.","volume":"55","author":"Schellong","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"coi250061r26","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3109\/0284186X.2015.1016624","article-title":"Predicting radiation-induced valvular heart damage.","volume":"54","author":"Cella","year":"2015","journal-title":"Acta Oncol"},{"issue":"4","key":"coi250061r27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1136\/heartjnl-2015-308765","article-title":"Radiation-induced valvular heart disease.","volume":"102","author":"Gujral","year":"2016","journal-title":"Heart"},{"issue":"1","key":"coi250061r28","first-page":"7","article-title":"Mediastinal irradiation and valvular heart disease.","volume":"8","author":"Patil","year":"2022","journal-title":"Cardiooncology"},{"issue":"8","key":"coi250061r29","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1200\/JCO.2003.04.173","article-title":"Cardiovascular disease as a long-term complication of treatment for testicular cancer.","volume":"21","author":"Huddart","year":"2003","journal-title":"J Clin Oncol"},{"issue":"11","key":"coi250061r30","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31251","article-title":"Treatments affecting splenic function as a risk factor for valvular heart disease in Childhood Cancer Survivors: a DCCSS-LATER study.","volume":"71","author":"Houtman","year":"2024","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"coi250061r31","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.amjcard.2015.11.027","article-title":"Assessment of valvular disorders in survivors of Hodgkin\u2019s lymphoma treated by mediastinal radiotherapy \u00b1 chemotherapy.","volume":"117","author":"Bijl","year":"2016","journal-title":"Am J Cardiol"},{"issue":"6","key":"coi250061r32","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk.","volume":"175","author":"van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"key":"coi250061r14","unstructured":"Final report summary\u2014PROCARDIO (cardiovascular risk from exposure to low-dose and low-dose-rate ionizing radiation. European Commission. Accessed September 12, 2024. https:\/\/cordis.europa.eu\/project\/id\/295823\/reporting"},{"key":"coi250061r16","unstructured":"Lead organizations: NCI network trial development and conduct. National Cancer Institute. Accessed September 4, 2025. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/trial-development"},{"key":"coi250061r21","unstructured":"Hirosoft. Accessed September 12, 2024. https:\/\/hirosoft.com\/"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2839918\/jamaoncology_aho_glele_2025_oi_250061_1765564182.41141.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:00:51Z","timestamp":1766073651000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2839918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.3863","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}